Atlas Trials

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Clinical trial NCT03441360 · COMPLETED

Trial details

NCT number
NCT03441360
Sponsor
Eisai Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory RhabdomyosarcomaNon-rhabdomyosarcoma Soft Tissue SarcomaEwing Sarcoma
Start date
2018-04-17
Primary completion
2021-01-07
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.